We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
HOLX Launches BustTheMyth Campaign for Breast Health Awareness
Read MoreHide Full Article
Hologic, Inc. (HOLX - Free Report) entered the Breast Cancer Awareness Month by ringing the Nasdaq opening bell for the 18th year. As part of this annual tradition, Hologic launched a comprehensive patient education campaign named BustTheMyth. The campaign is aimed at dispelling myths about breast cancer, mammograms and breast density.
The latest announcement highlights Hologic’s commitment to advancing technology and improving patient outcomes across the continuum of breast health.
Significance of Hologic’s BustTheMyth Campaign
According to the data released by the National Cancer Institute, breast cancer is the world’s most common cancer among women, affecting one in every eight women in their lifetime. When detected early, breast cancer is highly treatable, with a five-year survival rate of 99%. Despite the prevalence of breast cancer and the benefits of early detection, more than 40% of women in the United States reported skipping potentially life-saving breast cancer screenings. The primary reasons behind women skipping or delaying a recommended exam are not knowing the importance of the screening, anxiety about the exam, lack of time or concerns about pain or discomfort.
As a leading women’s health organization, Hologic aims to support women at every stage of their health journey, including advocating for change and increasing awareness about the importance of breast cancer screening and early detection. The campaign focuses on women empowerment by encouraging them to prioritize themselves and take charge of their health with confidence.
More on the News
Hologic’s educational campaign addresses many deterrents to screening by dispelling common myths, helping women learn the truth about who needs a mammogram, and more. Some of the facts regarding breast cancer are that 85% of women diagnosed with breast cancer have no family history and breast density cannot be felt; it is determined by a mammogram.
Hologic’s 3D Mammography exam is the only FDA-approved mammogram. The exam is best for women with dense breasts (when compared to 2D alone).
Recent Development by Hologic
In July, the company completed its previously announced acquisition of Endomagnetics Ltd (Endomag), a privately held UK-based developer of breast cancer surgery technologies, for approximately $310 million. This strategic move is aimed at bolstering Hologic's breast surgery portfolio, offering surgeons and radiologists an expanded range of innovative solutions for breast cancer procedures.
Industry Propects Favor Hologic
Per a Market Insights Future report, the women healthcare market was valued at $7.9 billion in 2023 and is projected to grow from $8.22 billion in 2024 to $10.9 billion by 2032, exhibiting a compound annual growth rate of 3.58% during the period. The key factors influencing market growth are the rising frequency of chronic health conditions, increasing women’s biological issues and advanced treatment.
Latest Updates From Hologic’s Peers
In the women's healthcare space, Hologic faces competition from some prominent MedTech players. These companies are also making notable developments in their respective categories.
Evofem Biosciences, Inc. (EVFM - Free Report) ,one of the major competitors of Hologic, recently entered into a market development collaboration with Pearsanta, Inc. to focus on the latter’s blood-based diagnostic test for endometriosis — Mitomic. Endometriosis is a chronic disease associated with severe, life-impacting pain. It affects approximately one in ten women of reproductive age around the world (approximately 190 million women and girls), according to the World Health Organization.
The company also received a U.S. patent for the composition and methods used in producing its Phexxi vagina gel. Phexxi is the first and only FDA-approved hormone-free, locally-acting contraceptive gel.
Aspira Women's Health , another peer of Hologic, is a bio-analytical-based women’s health company focused on the development of gynecologic disease diagnostic tools. Earlier this year, the company launched an updated OvaWatch ovarian cancer risk assessment test after completing all appropriate pre-launch activities. OvaWatch uses an AI-powered algorithm to assess the malignancy risk of adnexal masses. With a negative predictive value of 99%, OvaWatch can help physicians confidently determine the appropriate care plan over time.
Additionally, in August, the company inked a definitive agreement with Dorsata, a healthcare software company, to create a protocol workflow tool for the clinical treatment of adnexal masses.
Another notable competitor of Hologic is Dare Bioscience (DARE - Free Report) , which reported favorable data from the postcoital test clinical study of Ovaprene earlier this year. Ovaprene is an investigational hormone-free, intravaginal monthly product candidate currently in clinical development for pregnancy prevention. Additionally, the company achieved technological proof of concept for DARE-LARC1 — a potential new class of long-acting, reversible contraceptive.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
HOLX Launches BustTheMyth Campaign for Breast Health Awareness
Hologic, Inc. (HOLX - Free Report) entered the Breast Cancer Awareness Month by ringing the Nasdaq opening bell for the 18th year. As part of this annual tradition, Hologic launched a comprehensive patient education campaign named BustTheMyth. The campaign is aimed at dispelling myths about breast cancer, mammograms and breast density.
The latest announcement highlights Hologic’s commitment to advancing technology and improving patient outcomes across the continuum of breast health.
Significance of Hologic’s BustTheMyth Campaign
According to the data released by the National Cancer Institute, breast cancer is the world’s most common cancer among women, affecting one in every eight women in their lifetime. When detected early, breast cancer is highly treatable, with a five-year survival rate of 99%. Despite the prevalence of breast cancer and the benefits of early detection, more than 40% of women in the United States reported skipping potentially life-saving breast cancer screenings. The primary reasons behind women skipping or delaying a recommended exam are not knowing the importance of the screening, anxiety about the exam, lack of time or concerns about pain or discomfort.
As a leading women’s health organization, Hologic aims to support women at every stage of their health journey, including advocating for change and increasing awareness about the importance of breast cancer screening and early detection. The campaign focuses on women empowerment by encouraging them to prioritize themselves and take charge of their health with confidence.
More on the News
Hologic’s educational campaign addresses many deterrents to screening by dispelling common myths, helping women learn the truth about who needs a mammogram, and more. Some of the facts regarding breast cancer are that 85% of women diagnosed with breast cancer have no family history and breast density cannot be felt; it is determined by a mammogram.
Hologic’s 3D Mammography exam is the only FDA-approved mammogram. The exam is best for women with dense breasts (when compared to 2D alone).
Recent Development by Hologic
In July, the company completed its previously announced acquisition of Endomagnetics Ltd (Endomag), a privately held UK-based developer of breast cancer surgery technologies, for approximately $310 million. This strategic move is aimed at bolstering Hologic's breast surgery portfolio, offering surgeons and radiologists an expanded range of innovative solutions for breast cancer procedures.
Industry Propects Favor Hologic
Per a Market Insights Future report, the women healthcare market was valued at $7.9 billion in 2023 and is projected to grow from $8.22 billion in 2024 to $10.9 billion by 2032, exhibiting a compound annual growth rate of 3.58% during the period. The key factors influencing market growth are the rising frequency of chronic health conditions, increasing women’s biological issues and advanced treatment.
Latest Updates From Hologic’s Peers
In the women's healthcare space, Hologic faces competition from some prominent MedTech players. These companies are also making notable developments in their respective categories.
Evofem Biosciences, Inc. (EVFM - Free Report) ,one of the major competitors of Hologic, recently entered into a market development collaboration with Pearsanta, Inc. to focus on the latter’s blood-based diagnostic test for endometriosis — Mitomic. Endometriosis is a chronic disease associated with severe, life-impacting pain. It affects approximately one in ten women of reproductive age around the world (approximately 190 million women and girls), according to the World Health Organization.
The company also received a U.S. patent for the composition and methods used in producing its Phexxi vagina gel. Phexxi is the first and only FDA-approved hormone-free, locally-acting contraceptive gel.
Aspira Women's Health , another peer of Hologic, is a bio-analytical-based women’s health company focused on the development of gynecologic disease diagnostic tools. Earlier this year, the company launched an updated OvaWatch ovarian cancer risk assessment test after completing all appropriate pre-launch activities. OvaWatch uses an AI-powered algorithm to assess the malignancy risk of adnexal masses. With a negative predictive value of 99%, OvaWatch can help physicians confidently determine the appropriate care plan over time.
Additionally, in August, the company inked a definitive agreement with Dorsata, a healthcare software company, to create a protocol workflow tool for the clinical treatment of adnexal masses.
Another notable competitor of Hologic is Dare Bioscience (DARE - Free Report) , which reported favorable data from the postcoital test clinical study of Ovaprene earlier this year. Ovaprene is an investigational hormone-free, intravaginal monthly product candidate currently in clinical development for pregnancy prevention. Additionally, the company achieved technological proof of concept for DARE-LARC1 — a potential new class of long-acting, reversible contraceptive.